, Tracking Stock Market Picks
Enter Symbol:
Rating: HZNP
Buy $31
down 17.00 %

Horizon Pharma Inc (NASDAQ: HZNP) reiterated to Buy with price target $31 by Jefferies

Tuesday,  Jan 19, 2016  10:25 AM ET by Betsy O'Brien Harrison

Jefferies reiterated Horizon Pharma Inc (NASDAQ: HZNP) to Buy with price target $31. Previously Jefferies reiterated Horizon Pharma Inc (NASDAQ: HZNP) to Buy
on 11/23/2015, when the stock price was $21.97. Since then, Horizon Pharma Inc's stock price has lost 17% as of 01/19/2016's recent price of $18.33.
If you would have followed the previous Jefferies's recommendation on HZNP, you would have lost 17% of your investment in 57 days.

Horizon Pharma, Inc. (Horizon) is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. On April 23, 2011, the United States Food and Drug Administration, approved DUEXIS (formerly HZT-501), a tablet formulation containing a fixed-dose combination of ibuprofen and famotidine in a single pill. The Company?s other product, LODOTRA (NP-01), is a programmed release formulation of low-dose prednisone that is marketed in Europe by the Company?s distribution partner, Mundipharma International Corporation Limited (Mundipharma). As of December 31, 2010, Horizon completed multiple Phase III clinical trials of LODOTRA. In addition to these product candidates, the Company has a pipeline of earlier-stage product candidates to treat pain-related diseases and chronic inflammation.

Jefferiess' research efforts cover U.S. & International equity, high yield, convertibles, derivatives and option strategies, investment grade fixed income, post-reorganization securities, as well as special situations and quantitative research. Our team of more than 150 research professionals covers nearly 1,200 companies in more than 40 industries worldwide. Our analysts focus on identifying emerging industry themes while providing in-depth, thought provoking, objective research.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy